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The stellate cell is the key regulator cell in the development
of liver ﬁbrosis and cirrhosis. After an injury (which can be
viral, toxic, auto-immune or metabolic), the stellate cell
gets activated and produces an increase in the extracellular
matrix in the liver; this can lead to ﬁbrosis and cirrhosis.
Patients with severe liver ﬁbrosis and/or end stage liver cir-
rhosis can suffer from jaundice, bleeding from oesophageal
varices, development of ascites and hepatic encephalopathy
and carry a risk to develop a hepatocellular carcinoma. Liver
transplantation is at this moment the only ‘curative’ option.
If a liver transplantation is not possible, these ﬁbrosis re-
lated complications often lead to the death of the patient.
Although the diagnosis of liver ﬁbrosis is made by an invasive
liver biopsy, this ‘golden standard’ carries a substantial
number of complications and inter- and/or intra agreement
correlations are not optimal. Recently the interest for non-
invasive (serum) markers for liver ﬁbrosis have been studied.
The features of an ideal marker for liver ﬁbrosis are:
• Liver speciﬁc
• Levels not inﬂuenced by alterations in liver, renal or
reticuloendothelial function
• Measurement of one of more of the following processes
Stage of ﬁbrosis
Activity of matrix deposition
Activity of matrix removal
• Easy to perform
Actually there are direct and indirect markers of liver
ﬁbrosis. A direct marker is a marker of matrix turnover
with relationship to ECM deposition and removal. Indirect
markers use ‘standard’ laboratory test which have not
necessary direct correlation to matrix turnover. However
these actual markers (direct and indirect), although
promising, lack perfomance in earlier stages of ﬁbrosis.
They also need validation by independent groups.
Liver stifness measurement by elastography is an alternative
promising non-invasive technique to distinguish mild from
severe ﬁbrosis.
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The incidence of hepatocellular carcinoma (HCC) is
increasing worldwide. The overall survival of patients
with HCC is grim because most patients are diagnosed
late, when curative treatment is not possible. So early
diagnosis of hepatocelluar carcinoma (HCC) is still a great
challenge for clinical practice. Image techniques as well
as pathological examination are expensive or invasive and
operator dependent. Obviously, serum markers of HCC are
desperately required so as to make early diagnosis and
patient’s follow up practical. The ideal biomarkers should be
sensitive, speciﬁc, noninvasive, reproducible, inexpensive
and acceptable to patients. Up to now, the so called tumor
markers like AFP, liver enzymes, cytokines as well as some
special glycoproteins, though helpful, are not sensitive and
speciﬁc enough for HCC early diagnosis.
On the other hand, the knowledge on independent predic-
tors of HCC is increasing. These predicators include virus
infection, BMI (body mass index), diabetes, low platelet
count or some special genotypes of predisposing genes.
The establishment of several interesting predictive
diagnostic models on liver ﬁbrosis/cirrhosis suggests that
mathematic predictive model, based on large sample
size and follow up study, might be of higher sensitivity,
speciﬁcity and feasibility in clinical application. According
to our preliminary research, here we suggest to pay
attention to the establishment and application of this kind
of multiparameter diagnostic models clinically, so as to
improve the early diagnosis of HCC in a more economical
and feasible way.
In summary, although many studies of newer tumor markers
as well as independent predicators have been published, the
existing comments on these markers have many limitations.
These newer markers, including GPC-3, GP73, AFP-L3, as
well as our suggested putative multiparameters diagnostic
models should be evaluated further in properly designed
collaborative longitudinal studies.
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Background and Aims: Aberrant activation of oncogenes,
such as Ras, likely contributes to the development
of hepatocarcinoma (HCC) making Ras a target for
cancer therapy. We evaluated in vivo the effect of
intraperitoneal injection of the Ras inhibitor S-trans, trans-
farnesylthiosalicyclic acid (FTS) on Ras activation and the
development of preneoplastic liver lesions in rats repeatedly
injected with diethylnitrosamine (DEN).
Methods and Results: FTS prevents the development of
macroscopic liver nodules and reduces liver expression and
overall surface of the tumour marker GSTp as assessed by
Western blotting and immunohistochemistry. FTS abrogates
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